{{Rsnum
|rsid=5275
|Gene=PTGS2
|Chromosome=1
|position=186673926
|Orientation=minus
|GMAF=0.3586
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PTGS2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 12.6 | 50.5 | 36.9
| HCB | 0.8 | 35.6 | 63.6
| JPT | 3.6 | 43.6 | 52.7
| YRI | 34.5 | 54.2 | 11.3
| ASW | 26.3 | 63.2 | 10.5
| CHB | 0.8 | 35.6 | 63.6
| CHD | 2.8 | 31.8 | 65.4
| GIH | 10.2 | 52.0 | 37.8
| LWK | 32.4 | 52.4 | 15.2
| MEX | 8.8 | 43.9 | 47.4
| MKK | 21.8 | 56.4 | 21.8
| TSI | 7.1 | 42.4 | 50.5
| HapMapRevision=28
}}[[rs5275]], also known as exon1-+837T>C, is a SNP in the [[PTGS2]] gene.

A study of 635 Caucasian [[bladder cancer]] patients found a reduced risk associated with the minor (C) allele of [[rs5275]], (odds ratio 0.68, CI: 0.54-0.87, p=0.002, remaining significant after multiple comparison adjustment).{{PMID|18381966}}

{{PMID|19219602}} (T;T) genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better survival when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in [[colorectal cancer]]

{{PMID Auto
|PMID=19455278
|Title=Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population
}}

{{PMID Auto
|PMID=19748095
|Title=Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome
}}
{{PMID Auto
|PMID=19820421
|Title=The Effect of Genetic Polymorphisms of Cyclooxygenase 2 on Acute Pancreatitis in Turkey
}}

{{PharmGKB
|RSID=rs5275
|Name_s=PTGS2 exon10+837T>C
|Gene_s=PTGS2
|Feature=
|Evidence=PubMed ID:19773451
|Annotation=Risk or phenotype-associated allele: T. Phenotype: The TT genotype was associated with lower risk for severe pain. Study size: 667. Study population/ethnicity: Non-hispanic Caucasian patients with lung neoplasms, Texas; M. D. Anderson Cancer Center. Significance metric(s): OR = 0.33 (0.11-0.97); p = 0.04. Type of association: CO.
|Drugs=
|Drug Classes=
|Diseases=Pain
|Curation Level=Curated
|PharmGKB Accession ID=PA165349772
}}
{{PMID Auto
|PMID=20033767
|Title=Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis
}}

{{PMID Auto
|PMID=19773451
|Title=Role of inflammation gene polymorphisms on pain severity in lung cancer patients
|OA=1
}}

{{PMID Auto
|PMID=20472470
|Title=Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding
}}
{{PMID Auto
|PMID=20559705
|Title=Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk
|OA=1
}}
{{PMID Auto
|PMID=20686383
|Title=Cyclooxygenase-2 gene polymorphisms and risk of cervical cancer in a North Indian population
}}

{{PharmGKB
|RSID=rs5275
|Name_s=PTGS2:8473T>C
|Gene_s=PTGS2
|Feature=
|Evidence=PubMed ID:14604894; PubMed ID:16959787
|Annotation=Increased risk for non-small-cell lung cancer, basal cell carcinoma.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145106
}}

{{PharmGKB
|RSID=rs5275
|Name_s=PTGS2: 8473T>C
|Gene_s=PTGS2
|Feature=
|Evidence=PubMed ID:16678543
|Annotation=SNP has a significant association with the level of PTGS2 expression.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161615653
}}

{{PharmGKB
|RSID=rs5275
|Name_s=PTGS2:8473T>C, COX-2 8473T>C
|Gene_s=PTGS2
|Feature=
|Evidence=PubMed ID:19219602
|Annotation=Risk or phenotype-associated allele: T. Phenotype: Homozygous TT genotype was associated with better PFS and overall survival in patients with advanced colorectal cancer treated with XELOX chemotherapy. Study size: 76. Study population/ethnicity: Colorectal Neoplasms; Korea; Asian. Significance metric(s): HR = 0.47, p = 0.046 (PFS); HR = 0.16, p = 0.013 (OS) Type of association: CO.
|Drugs=capecitabine; oxaliplatin
|Drug Classes=
|Diseases=Colorectal Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165291665
}}

{{PMID Auto
|PMID=21816595
|Title=A Promoter polymorphism (rs17222919, -1316T/G) of ALOX5AP is associated with intracerebral hemorrhage in Korean population
}}

{{PMID Auto
|PMID=21705955
|Title=Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility
}}

{{PMID|16205694|OA=1
}} Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.

{{PMID|17066444}} Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism.

{{PMID|17171651}} Cyclooxygenase-2 polymorphisms in Parkinson's disease.

{{PMID|17181859|OA=1
}} Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk.

{{PMID|17214885|OA=1
}} A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study.

{{PMID|17356794}} Association of common polymorphisms in inflammatory genes with risk of developing cancers of the upper aerodigestive tract.

{{PMID|17404026}} Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population.

{{PMID|17999989}} Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.

{{PMID|18085997}} Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.

{{PMID|18454203|OA=1
}} Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression.

{{PMID|18471798|OA=1
}} Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis.

{{PMID|18768181|OA=1
}} Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study.

{{PMID|18989535}} Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease.

{{PMID|18992148|OA=1
}} Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study.

{{PMID|19197984|OA=1
}} Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions.

{{PMID|19318492|OA=1
}} Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.

{{PMID|19437564|OA=1
}} No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk.

{{PMID|19505919|OA=1
}} Toll-like receptor signaling pathway variants and prostate cancer mortality.

{{PMID|19890662}} TNF superfamily gene polymorphism as prognostic factor in early breast cancer.

{{PMID|19930591|OA=1
}} Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

{{PMID|20444268|OA=1
}} Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets.

{{PMID|20803508}} Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study.

{{PMID|20811626|OA=1
}} Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.

{{PMID|21042835}} Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.

{{PMID|21283657|OA=1
}} Gallbladder cancer predisposition: a multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes.

{{PMID|21304218}} Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis.

{{PMID|21371074|OA=1
}} The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.

{{PMID|22023987}} Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort.

{{PMID|22037828}} Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features.

{{PMID|22385256}} A genetic variant in 3'-untranslated region of cyclooxygenases-2 gene is associated with risk of gastric cancer in a chinese population.

{{PMID|22487732}} Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5275
|overall_frequency_n=52
|overall_frequency_d=122
|overall_frequency=0.42623
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=45
|n_articles=3
|n_articles_annotated=2
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23444045
|Title=Association between a functional variant at PTGS2 gene 3'UTR and its mRNA expression in lymphoblastoid cell lines
}}

{{PMID Auto
|PMID=23531863
|Title=An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition
}}

{{PMID Auto
|PMID=24194923
|Title=Interactions between Diet, Lifestyle and IL10, IL1B, and PTGS2/COX-2 Gene Polymorphisms in Relation to Risk of Colorectal Cancer in a Prospective Danish Case-Cohort Study
|OA=1
}}

{{PMID Auto
|PMID=22464751
|Title=SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors.
}}

{{PMID Auto
|PMID=23029430
|Title=Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma.
|OA=1
}}

{{PMID Auto
|PMID=25166592
|Title=Intestinal PTGS2 mRNA Levels, PTGS2 Gene Polymorphisms, and Colorectal Carcinogenesis
}}

{{PMID Auto
|PMID=25214704
|Title=Association of the Three Common SNPs of Cyclooxygenase-2 Gene (rs20417, rs689466, and rs5275) with the Susceptibility of Breast Cancer: An Updated Meta-Analysis Involving 34,590 Subjects
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}